Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse

Journal of Veterinary Pharmacology and Therapeutics
L R SomaRaymond C Boston

Abstract

Intravenous (iv), subcutaneous (sq), and topical (tp) lidocaine was administered to six horses in a cross-over, randomized design study. Samples were collected for up to 72 hr. Compartmental models were used to investigate the pharmacokinetics of (LD) and its metabolites 3-hydroxylidocaine (3-OH), 4-hydroxylidocaine (4-OH), and monoethylglycinexylidide (MEGX). Metabolites 3-OH and 4-OH were present in conjugated forms, whereas LD and metabolite MEXG were present primarily in the un-conjugated form. Plasma concentrations of LD after iv administration (100 mg) were described by three-compartment model with an additional three compartments to describe the elimination of metabolites. Median (range) elimination micro-constants (Ke ) for LD, 3-OH, 4-OH, and MEXG were 4.12 (2.62-6.23), 1.25 (1.10-2.15), 1.79 (1.22-2.39), and 1.69 (1.03-1.99)/hr, respectively. Median (range) values of alpha (t½α ), beta (t½β ), and gamma (t½γ ) half-lives were 0.08 (0.07-0.13), 0.57 (0.15-1.25), and 4.11 (0.52-7.36) hr. Plasma concentrations of LD after sq (200 mg) administration were described by absorption and two-compartment elimination model. The median (range) of the LD absorption half-life (t½ab ) was 0.47 (0.29-0.61) hr. The Ke for LD, 3-OH, 4-O...Continue Reading

References

Jul 1, 1979·Clinical Pharmacokinetics·G T Tucker, L E Mather
Aug 1, 1977·British Journal of Clinical Pharmacology·R L NationM Selig
Apr 17, 1976·British Medical Journal·L F PrescottR G Talbot
Oct 1, 1992·Biopharmaceutics & Drug Disposition·R W SallieR Williams
May 1, 1990·Pharmaceutical Research·Y K TamM R Gray
Mar 1, 1987·Journal of Veterinary Pharmacology and Therapeutics·L R EngelkingD J Greenblatt
Apr 1, 1987·Journal of Pharmacokinetics and Biopharmaceutics·A H ThomsonB Whiting
Dec 1, 1985·Journal of Pharmacokinetics and Biopharmaceutics·K S Pang
Oct 1, 1972·British Journal of Anaesthesia·D B ScottP Frisch
Jan 1, 1969·Annual Review of Pharmacology·F P Luduena
Nov 1, 1972·Anesthesiology·R H De JongL De Oliveira
Apr 1, 1982·Clinical Pharmacology and Therapeutics·L A BauerJ P Shea
Mar 1, 1981·Computer Programs in Biomedicine·R C BostonM Berman
Feb 1, 1995·Annals of Neurology·M C RowbothamH L Fields
Mar 15, 1994·Biochemical Pharmacology·K TanakaY Funae
Feb 3, 1996·The Veterinary Record·J KristinssonT Johannesson
Jun 1, 1994·Journal of Pharmaceutical Sciences·P Singh, M S Roberts
Jan 14, 1999·Journal of Veterinary Pharmacology and Therapeutics·J D HarkinsT Tobin
Jan 5, 2002·Journal of Pharmacokinetics and Pharmacodynamics·S L Beal
Jul 30, 2002·Southern Medical Journal·Charles E Argoff
Sep 5, 2002·Current Pain and Headache Reports·Charles E Argoff
Mar 6, 2003·Journal of Clinical Pharmacology·Arnold R GammaitoniBradley S Galer
Jun 1, 1965·British Journal of Anaesthesia·D P BRAID, D B SCOTT
Sep 25, 2003·Metabolism: Clinical and Experimental·Darko StefanovskiRaymond C Boston
Dec 17, 2004·Journal of Veterinary Pharmacology and Therapeutics·P L Toutain, A Bousquet-Mélou
Feb 5, 2005·American Journal of Veterinary Research·Paul C MillsSheree E Cross
Dec 6, 2005·The Veterinary Journal·P C Mills, S E Cross
Jan 18, 2006·Veterinary Surgery : VS·Erin MaloneJonathan Lumsden
Jan 20, 2006·Journal of Veterinary Pharmacology and Therapeutics·P C Mills, S E Cross
Aug 19, 2007·Veterinary Anaesthesia and Analgesia·Lori A BidwellJohn P Caron
Sep 8, 2007·Journal of the American Animal Hospital Association·Jeff KoTodd Haydon
Jul 22, 2008·Journal of Veterinary Pharmacology and Therapeutics·J C H KoA B Weil
Jun 23, 2010·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Samantha A NelisP Nicholas Shaw
Oct 23, 2010·Drug Testing and Analysis·James P ScarthTiia Kuuranne
Apr 2, 2011·American Journal of Veterinary Research·Marlis L RezendeEugene P Steffey
Jul 21, 2012·Dental Traumatology : Official Publication of International Association for Dental Traumatology·Alaa Al-MusawiLars Andersson

❮ Previous
Next ❯

Citations

Dec 17, 2021·Journal of Veterinary Pharmacology and Therapeutics·Daniela LuethyJoann Slack

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.